Trial
NCT05561530
A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Aligos Therapeutics
Collaborators
—
Condition
Chronic Hepatitis B
Intervention
ALG-125755
Why stopped
Single doses demonstrated an acceptable safety profile and antiviral activity at all doses evaluated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-15